Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET—A Decade of Post-Authorization Insights

Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET—A Decade of Post-Authorization Insights

Florbetaben (FBB) is a radiopharmaceutical approved by the FDA and EMA in 2014 for the positron emission tomography (PET) imaging of brain amyloid deposition in patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline. Initially, th...

Full description

Bibliographic Details
Main Authors: Aleksandar Jovalekic, Santiago Bullich, Núria Roé-Vellvé, Guilherme Domingues Kolinger, Lorelei R. Howard, Floriana Elsholz, Mariana Lagos-Quintana, Beatriz Blanco-Rodriguez, Esther Pérez-Martínez, Rossella Gismondi, Audrey Perrotin, Marianne Chapleau, Richard Keegan, Andre Mueller, Andrew W. Stephens, Norman Koglin
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Pharmaceuticals
Subjects:
amyloid
Alzheimer’s disease
Centiloid
florbetaben
mild cognitive impairment
quantification
Online Access:https://www.mdpi.com/1424-8247/17/12/1648

Internet

https://www.mdpi.com/1424-8247/17/12/1648

Similar Items